Triptolide and its pro-drug Minnelide target high-risk MYC amplified medulloblastoma in preclinical models

Overview of attention for article published in Journal of Clinical Investigation, June 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 77,615 followers.

RT @jclinicalinvest: Minnelide reduces the proliferation and spread of medulloblastoma by inhibiting MYC signaling in preclinical models. h…

Minnelide reduces the proliferation and spread of medulloblastoma by inhibiting MYC signaling in preclinical models. https://t.co/LaLPaIi2SW @muschollings @ResearchMUSC @musckids https://t.co/vEOr0IeZBW

Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models https://t.co/i0rcJiCZNH

So proud of Dr. Jeza Rodriguez Blanco @jezabelrblanco @muschollings for her new paper in @jclinicalinvest JCI - Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models https://t.co/ZQejT8zndp

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.